Ever since Medicare proposed to sharply limit the coverage of the controversial Alzheimer’s drug Aduhelm, the agency has been flooded with fiery pleas. Groups representing patients insisted that the federalRead More
Ever since Medicare proposed to sharply limit the coverage of the controversial Alzheimer’s drug Aduhelm, the agency has been flooded with fiery pleas. Groups representing patients insisted that the federalRead More